Literature DB >> 2844672

Antiarthritic synergism of combined oral and parenteral chrysotherapy. II. Increased inhibition of activated leukocyte oxygen burst by combined gold action.

A E Finkelstein1, M Ladizesky, R Borinsky, E Kohn, I Ginsburg.   

Abstract

We have observed an antiarthritic effect of combined chrysotherapy in adjuvant arthritis. Since superoxide radicals (O2-) are potent mediators of rheumatoid inflammation, we studied the combined effect of auranofin (AF) and injectable golds on luminol-dependent chemiluminescence (LDCL) and O2- generation by cytochrome-c reduction of activated leukocytes by different receptor-mediated stimuli: phorbol myristic acetate, 10(-6) M; f-Met-Leu-Phe, 10(-6) M; and poly-L-histidine, 10(-5) M. AF, 0.6 and 0.9 micrograms Au/ml, inhibited 34 and 58% of O2- generation, respectively; the addition to AF of 0.3 micrograms Au/ml of gold thiosulfate (GTS) increased this inhibition to 84 and 97% of the oxygen burst. Similar synergistic potentiation inhibition was obtained by LDCL. When the inhibition of O2- generation by the combined action of AF and GTS was compared with AF + gold sodium thiomalate (GTM), only GTS showed an activation on AF's inhibition of the oxygen burst of human leukocytes. The ligand thiosulfate in equimolar concentrations to GTS had a statistically significant (P less than 0.01) inhibitory effect on AF's blockade of O2- generation during the first 5 min of the interaction with the PMNs; thiomalate had no effect. Sequential pretreatment of PMNs with AF and GTS on O2- generation revealed that for synergism of combined gold action to take place, the cell membrane had to be subjected first to the action of oral gold or to the simultaneous combined action of oral and parenteral gold.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2844672     DOI: 10.1007/bf00915773

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  18 in total

1.  Leukocytes as secretory organs of inflammation.

Authors:  G Weissmann; R B Zurier; S Hoffstein
Journal:  Agents Actions       Date:  1973-12

2.  Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent.

Authors:  B M Babior; R S Kipnes; J T Curnutte
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

Review 3.  Tissue injury in inflammation. Oxidants, proteinases, and cationic proteins.

Authors:  P M Henson; R B Johnston
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

4.  Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis.

Authors:  D J Wallace; A L Metzger; K K White
Journal:  Arthritis Rheum       Date:  1985-05

5.  Chemotactic factor-induced generation of superoxide radicals by human neutrophils: effect of metabolic inhibitors and antiinflammatory drugs.

Authors:  L Simchowitz; J Mehta; I Spilberg
Journal:  Arthritis Rheum       Date:  1979-07

6.  Auranofin. New oral gold compound for treatment of rheumatoid arthritis.

Authors:  A E Finkelstein; D T Walz; V Batista; M Mizraji; F Roisman; A Misher
Journal:  Ann Rheum Dis       Date:  1976-06       Impact factor: 19.103

7.  Free radicals and inflammation: protection of synovial fluid by superoxide dismutase.

Authors:  J M McCord
Journal:  Science       Date:  1974-08-09       Impact factor: 47.728

8.  Protective factors against oxygen free radicals and hydrogen peroxide in rheumatoid arthritis synovial fluid.

Authors:  P Biemond; A J Swaak; J F Koster
Journal:  Arthritis Rheum       Date:  1984-07

9.  Bacteria and zymosan opsonized with histone, dextran sulfate, and polyanetholesulfonate trigger intense chemiluminescence in human blood leukocytes and platelets and in mouse macrophages: modulation by metabolic inhibitors in relation to leukocyte-bacteria interactions in inflammatory sites.

Authors:  I Ginsburg; R Borinsky; M Lahav; K E Gillert; S Falkenberg; M Winkler; S Muller
Journal:  Inflammation       Date:  1982-12       Impact factor: 4.092

10.  Intractable rheumatoid arthritis. Treatment with combined cyclophosphamide, azathioprine, and hydroxychloroquine.

Authors:  D J McCarty; G F Carrera
Journal:  JAMA       Date:  1982-10-08       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.